| Date | Title | Description |
| 16.06.2026 | SonoThera Secures $125M: Ultrasound Reshapes Genetic Medicine | SonoThera, a biotechnology pioneer, just closed a significant Series B funding round. The South San Francisco-based firm secured $125 million. This oversubscribed financing fuels its revolutionary nonviral genetic medicine platform. The inv... |
| 10.06.2026 | SonoThera Raises $125 Million Series B To Advance Ultrasound-Mediated Genetic Medicines | SonoThera, a biotechnology company developing ultrasound-mediated nonviral genetic medicines, announced the closing of an oversubscribed $125 million Series B financing round to support the clinical advancement of its lead programs for Duch... |
| 10.06.2026 | SonoThera Raises $125M in Series B Funding | SonoThera, a South San Francisco, CA-based biotechnology company developing new genetic medicines, raised $125M in Series B funding.
The round was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bay... |
| 21.04.2026 | Lightcast Secures Major Funding, Redefines Single-Cell Analysis with Envisia Platform | Lightcast, a life science innovator, secured $27 million in funding. ARCH Venture Partners led the round. This capital fuels the 2026 commercial launch of its Envisia™ benchtop platform. Envisia marks a significant leap in single-cell analy... |
| 15.04.2026 | Lightcast Raises $27M in Funding | Lightcast, a Cambridge, UK-based life science tools company focused on functional single-cell analysis, raised $27M in funding.
The round was led by ARCH Venture Partners with participation from M Ventures, Illumina Ventures, +ND Capital, L... |
| 14.04.2026 | Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform | · Proceeds will help enhance workflows and expand single-cell functional assay portfolio
· Brad Crutchfield joins as advisor to support early access growth and global launch
CAMBRIDGE, England – April 14, 2026 – Lightcast, a pioneering life... |
| 12.01.2026 | Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team | T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., ... |
| 12.11.2025 | Hepta Unveils AI Liquid Biopsy for Chronic Disease | Hepta secures $6.7M. It pioneers AI-driven liquid biopsy for chronic diseases, starting with MASH. Its transformer AI platform analyzes cell-free DNA epigenomes. This delivers unparalleled precision in diagnosis. The non-invasive blood test... |
| 12.11.2025 | AI-Driven Biotech Iambic Secures Over $100M for Drug Discovery | Iambic, a San Diego AI-driven biotech, secured over $100M in funding. This capital fuels its advanced AI drug discovery platform and expanding clinical pipeline. The company rapidly advances novel therapies, like IAM1363, showing strong ant... |
| 11.11.2025 | Iambic Raises Over $100M in Funding | Iambic, a San Diego, CA-based clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, raised over $100M in funding.
Backers included Abingworth, Alexandria Ventur... |
| 10.11.2025 | Iambic: $100 Million Raised To Advance AI-Discovered Therapeutics And Platform Technologies | Iambic, a clinical-stage life science and technology company headquartered in San Diego, announced that it has raised more than $100 million in an oversubscribed financing round. The round drew participation from a broad group of new and ex... |
| 10.11.2025 | Hepta Emerges from Stealth with $6.7M to Pioneer AI-Driven Chronic Disease Liquid Biopsy | What You Should Know:
– Hepta, a biotechnology company focused on diagnosing chronic disease, has emerged from stealth announcing $6.7M in seed funding co-led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures,... |
| 06.11.2025 | Hepta: $6.7 Million Seed Funding Closed To Advance Liquid Biopsy-Based AI Diagnostics For Chronic Liver Disease | Hepta, a biotechnology company developing a transformer-based artificial intelligence platform to analyze the cell-free DNA epigenome, has emerged from stealth with $6.7 million in seed funding. The round was led by Felicis Ventures and Ill... |
| 07.10.2025 | Predicta Biosciences: $23.4 Million Series A Raised To Advance Diagnostic And Therapeutic Discovery Tools | Predicta Biosciences, a precision oncology company focused on developing advanced diagnostic and therapeutic discovery tools, has announced the close of a $23.4 million Series A funding round. The funding round was oversubscribed and led by... |
| 02.10.2025 | Predicta Biosciences Raises $23.4M in Series A Funding | Predicta Biosciences, a Cambridge, MA-based precision oncology company developing novel diagnostic and therapeutic discovery solutions, raised $23.4m in Series A funding.
The round was led by Engine Ventures with particiaption from Illumina... |
| 06.08.2025 | NuCicer Raises $11.5M in Series A Funding | NuCicer, a Davis, CA-based company which specializes in chickpea breeding and sustainable ingredient solutions, raised $11.5M Series A funding.
The round was led by Rhapsody Venture Partners, with participation from Leaps by Bayer and a ser... |
| 12.01.2024 | Illumina Ventures launches refreshed genomics startup accelerator program | Illumina’s independently managed venture capital firm has opened up the doors to the new evolution of its startup incubator dubbed Illumina Ventures Labs.
First announced in June 2023, Illumina Ventures said the new genomics-focused funding... |
| 19.09.2023 | 13th Investment for HERAN Partners: Broken String Biosciences (UK) | Cambridge, UK: Broken String Biosciences, a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, announced that it has closed a $15m Series A investment round, co-led ... |
| 18.09.2023 | Advancing gene therapy safety: Broken String raises $15M for DNA break mapping platform | UK-based biotech firm Broken String Biosciences is building a platform that according to the company, accelerates the characterisation of novel genome editing technologies. The Next Generation Sequencing (NGS)-based DNA break mapping platfo... |
| 18.09.2023 | UK’s Broken String Biosciences raises €14M to develop, commercialise its INDUCE-seq tech: Know more | Read this article in:
Cambridge-based Broken String Biosciences, a genomics company focused on creating safer cell and gene therapies, announced on Monday that it has raised $15M (approximately €14M) in a Series A round of funding.
The inve... |
| 21.06.2023 | Illumina Ventures to Launch Ventures Labs | Illumina Ventures, a San Francisco, CA-based genomics and precision health venture firm, has launched Illumina Ventures Labs.
Building on the foundation of the Illumina Accelerator program, Illumina Ventures Labs will operate and provide ac... |
| 25.05.2023 | The Week in AgriFoodTech: Pluton Biosciences bags $16.5m, Babylon Micro-Farms secures funds, José Andrés launches climate institute | This week, agtech companies Pluton Biosciences and Babylon Micro-Farms raised funds for microbial cover crops and vertical farms, respectively. Celebrity chef José Andrés teamed up with a university for a new food and climate institute, and... |
| 24.01.2023 | Illumina Ventures Announces Strategic New Additions to its Investment Team | Illumina Ventures, a genomics and precision health focused venture firm, announced additions to its investment team. Abhijit “Ron” Mazumder, PhD, MBA, joins as a Partner and Lisa Alderson, MBA as an Entrepreneur in Residence.
Latest Aithori... |
| 20.09.2021 | Illumina Ventures Closes $325M Fund | Illumina Ventures, a San Francisco, CA-based healthcare-focused venture firm, closed its second investment fund, at $325m.
The latest fund is anchored by Illumina, Inc. (Nasdaq: ILMN), with the majority of the total committed capital from o... |
| 20.09.2021 | Illumina Ventures sets sights on European genomics startups with new $325M fund | Illumina Ventures, the independently managed venture capital firm bankrolled by the DNA sequencing giant, has closed its second investment fund, amassing $325 million in new commitments.
The proceeds will be used to support genomics-focuse... |
| 20.09.2021 | Illumina Ventures sets sights on European genomics startups with new $325M fund | Illumina Ventures, the independently managed venture capital firm bankrolled by the DNA sequencing giant, has closed its second investment fund, amassing $325 million in new commitments.
RELATED: Delfi Diagnostics raises $100M for a new app... |
| 20.09.2021 | Evergrande is in trouble. But it probably won’t be a Lehman moment | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
It’s certainly eye-catching, but concerns that the collapse of Chinese property giant Evergrande ... |
| 20.09.2021 | Illumina Ventures : Closes $325 Million Fund | Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. The... |
| 20.09.2021 | Illumina Ventures closes $325M sophomore fund | Illumina Ventures has raised $325 million in commitments for its second fund. The California-based firm seeks to invest in the life sciences, clinical diagnostics and therapeutics sectors. Founded in 2016, the firm's portfolio includes heal... |
| 06.05.2020 | LetsGetChecked Closes $71 Million Series C | LetsGetChecked, a leading direct-to-consumer at-home health testing and insights company, today announced the closing of $71 million in its Series C round of financing.
Illumina Ventures and HLM Venture Partners co-led the round with new in... |
| 06.05.2020 | LetsGetChecked Closes $71 Million Series C | LetsGetChecked, a leading direct-to-consumer at-home health testing and insights company, today announced the closing of $71 million in its Series C round of financing.
Illumina Ventures and HLM Venture Partners co-led the round with new in... |
| 14.04.2020 | SwissDeCode selected by European Innovation Council for Covid-19 pitching event | SwissDeCode developed DNAFoil technology, a portable, self-administered, on-site DNA detection kit, which combines both food safety and compliance with regulatory bodies in a single tool. |
| 14.04.2020 | SwissDeCode selected by European Innovation Council for Covid-19 pitching event | |
| 29.12.2019 | Wrapping Up CLT’s 2019: Q4 Deals in the Queen City | An exciting Q4 in the Carolinas has left many startups looking forward to a successful 2020. We thought the best way to ring in the new year would be to look back at the most noteworthy fundings, deals, exits, mergers, and acquisitions duri... |
| 08.05.2019 | LunaPBC Raises $4.6M to Fuel Community-Owned Genomic & Health Data Platform | LunaPBC, founder of LunaDNA, the first community-owned genomic and health data platform, has raised $4.6 million from ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. The lates... |
| 11.01.2019 | Time is running out for healthcare startups to apply to the MedCity INVEST Pitch Perfect competition! | The deadline to apply for the 2019 competition was Jan. 15 but has been extended to February 8. Click on this link to apply!
In order to participate companies must fulfill at least one of these requirements:
Raised at least $1 million
Raise... |
| 26.11.2018 | Illumina Ventures leads €16M round for digital PCR firm Stilla Technologies | Illumina Ventures led a €16 million ($18 million) series A round for Stilla Technologies, a Paris-based developer of digital PCR solutions for genetic analysis.
The genomics-focused fund supported by Illumina was joined by Kurma Partners, L... |
| 17.10.2017 | Illumina Ventures raises $230m for debut fund | San Francisco-based Illumina Ventures has pulled in $230m for its debut fund. The vehicle received a $100m commitment f |
| 17.10.2017 | Term Sheet — Tuesday, October 17 | VCs + ICOs
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
Today, my colleague Robert Hackett got his hands on some hard data that backs up some of these claims. Here are the highlights:
... |
| 17.10.2017 |
Illumina Ventures Raises $230M Venture Capital Fund
| Illumina Ventures, the early-stage venture capital investor which was founded by San Diego-based life sciences equipment maker Illumina, says it has raised $230M for its first fund. The venture capital investment fund said it is focused on ... |
| 16.10.2017 | Illumina Ventures Raises $230M Fund to Support Genomics Startups | The venture capital firm founded by San Diego’s DNA instrument giant Illumina Inc. has raised a $230 million fund to fuel genomics startups.
The VC firm, called Illumina Ventures, was founded last year with a $100 million investment from Il... |
| 16.10.2017 | Illumina Ventures Closes First Venture Capital Fund, at $230M | Illumina Ventures, a San Francisco-based early-stage venture capital firm, closed its maiden fund, at $230m.
Launched with an initial $100m investment from Illumina, Illumina Ventures has then been supported by a mix of corporate, instituti... |
| 16.10.2017 | Illumina Ventures Founder talks about investment priorities for first $230M fund (Updated) | Illumina Ventures Founder Nicholas Naclerio responded to questions about its investment strategy and funding priorities in an email.
He said the fund invests in life science tools, clinical diagnostics, therapeutics, and other opportunities... |
| - | French biotech DNA Script raises $200 million, pushes forward with desktop DNA printer | Parisian life sciences technology company DNA Script has raised $200 million in a Series C funding round. The company has developed an alternative to traditional DNA synthesis, a proprietary mechanism it calls Enzymatic DNA Synthesis. This ... |
| - | Time is running out for healthcare startups to apply to the MedCity INVEST Pitch Perfect competition! | There’s never been a more exciting time in healthcare, particularly for entrepreneurs. Investment in digital health reached $14.2 billion last year, according to StartUp Health. Life science companies raised $23.3 billion across 1,308 deals... |
| - | Carl Icahn wants to bring back Illumina's ex-CEO 'immediately' as proxy fight intensifies | Carl Icahn told the Wall Street Journal that biotech company Illumina should bring back its former CEO "immediately."
The activist investor's remarks are the latest in a brewing proxy fight with Illumina over the company's $7.1 bi... |
| - | Illumina Ventures Founder talks about investment priorities for first $230M fund (Updated) | Early stage genomics businesses are the focus of Illumina Ventures’ first fund. Launched last year as the investment arm of biotech business Illumina, the firm has raised $230 million for the first fund, according to a news release.
So far ... |
